PE20060015A1 - Composiciones de liberacion prolongada que comprenden torasemida y un polimero formador de matriz - Google Patents

Composiciones de liberacion prolongada que comprenden torasemida y un polimero formador de matriz

Info

Publication number
PE20060015A1
PE20060015A1 PE2005000267A PE2005000267A PE20060015A1 PE 20060015 A1 PE20060015 A1 PE 20060015A1 PE 2005000267 A PE2005000267 A PE 2005000267A PE 2005000267 A PE2005000267 A PE 2005000267A PE 20060015 A1 PE20060015 A1 PE 20060015A1
Authority
PE
Peru
Prior art keywords
torasemide
prolonged release
forming polymer
compositions including
release compositions
Prior art date
Application number
PE2005000267A
Other languages
English (en)
Inventor
Alfonso Romero
Marta Guerrero
Antonio Guglietta
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060015(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of PE20060015A1 publication Critical patent/PE20060015A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPOSICIONES ORALES DE LIBERACION PROLONGADA QUE COMPRENDE EL PRINCIPIO ACTIVO TORASEMIDA, EN UNA PROPORCION DE 0,5 AL 20%; UN POLIMERO FORMADOR DE MATRICES, SELECCIONADOS DEL GRUPO DE: ACRILICOS, CELULOSICOS, BEHENATO DE GLICERILO, GOMA GUAR, GOMA XANTANA, QUITOSANO, GELATINA, ALCOHOL POLIVINILICO, SUS SIMILARES Y MEZCLAS DE ESTOS, LOS QUE SE ENCUENTRA EN UNA PROPORCION DE 1 AL 50%, ADEMAS COMPRENDEN UNO O MAS EXCIPIENTES ELEGIDOS ENTRE DILUYENTES, AGLUTINANTES, DISGREGANTES, LUBRICANTES Y SIMILARES. ESTAS COMPOSICIONES PRESENTAN UNA ACTIVIDAD DIURETICA Y MANTIENEN LA DIURESIS EN UN TIEMPO MAXIMO DE 24 HORAS Y PREFERENTEMENTE 12 HORAS, EVITANDO ASI POSIBLES PROBLEMAS DE NICTURIA
PE2005000267A 2004-03-25 2005-03-09 Composiciones de liberacion prolongada que comprenden torasemida y un polimero formador de matriz PE20060015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200400740A ES2244324B1 (es) 2004-03-25 2004-03-25 Composiciones diureticas de liberacion prolongada.

Publications (1)

Publication Number Publication Date
PE20060015A1 true PE20060015A1 (es) 2006-02-02

Family

ID=34962072

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000267A PE20060015A1 (es) 2004-03-25 2005-03-09 Composiciones de liberacion prolongada que comprenden torasemida y un polimero formador de matriz

Country Status (20)

Country Link
US (1) US20080187585A1 (es)
EP (1) EP1732517B1 (es)
JP (1) JP4871258B2 (es)
KR (1) KR101203763B1 (es)
CN (1) CN1946379B (es)
AR (1) AR048432A1 (es)
AU (1) AU2005227095B2 (es)
BR (1) BRPI0509165A (es)
CA (1) CA2562142C (es)
ES (2) ES2244324B1 (es)
MX (1) MXPA06010833A (es)
NO (1) NO336582B1 (es)
PA (1) PA8627401A1 (es)
PE (1) PE20060015A1 (es)
PL (1) PL1732517T3 (es)
PT (1) PT1732517T (es)
RU (2) RU2006137671A (es)
TW (1) TWI351957B (es)
UY (1) UY28809A1 (es)
WO (1) WO2005092291A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10463622B2 (en) * 2013-10-06 2019-11-05 Sarfez Pharmaceuticals, Inc. Treatments and formulations comprising Torsemide
US10596119B1 (en) * 2018-11-08 2020-03-24 Sarfez Pharmaceuticals, Inc. Methods of treatment comprising torsemide
WO2015050570A1 (en) * 2013-10-06 2015-04-09 Shah Salim Controlled-release formulations comprising torsemide
EP3031471A1 (en) * 2014-12-12 2016-06-15 Ceva Sante Animale Veterinary composition for the treatment of pulmonary edema associated with heart failure in domestic animals

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3305935C2 (de) * 1983-02-21 1985-05-30 Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn Kaliumneutrales Saluretikum mit antihypertensiver Wirkung
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8601204D0 (en) * 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
JP3586471B2 (ja) * 1991-06-25 2004-11-10 三菱ウェルファーマ株式会社 トラセミド含有医薬組成物
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
KR20020025217A (ko) * 1999-08-11 2002-04-03 추후보정 토르세미드 동질이상
HUP0600143A2 (en) * 2000-02-17 2006-10-28 Teva Pharma A stable pharmaceutical formulation comprising torsemide modification ii
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
MXPA06006677A (es) * 2003-12-12 2006-08-31 Penwest Pharmaceuticals Co Formas de dosis de torasemida de liberacion sostenida.

Also Published As

Publication number Publication date
NO20064834L (no) 2006-12-07
US20080187585A1 (en) 2008-08-07
ES2244324B1 (es) 2006-11-16
NO336582B1 (no) 2015-09-28
ES2632354T3 (es) 2017-09-12
WO2005092291A1 (en) 2005-10-06
EP1732517A1 (en) 2006-12-20
KR101203763B1 (ko) 2012-11-23
PA8627401A1 (es) 2005-11-25
UY28809A1 (es) 2005-07-29
RU2006137671A (ru) 2008-04-27
AU2005227095A1 (en) 2005-10-06
ES2244324A1 (es) 2005-12-01
BRPI0509165A (pt) 2007-09-11
EP1732517B1 (en) 2017-05-03
AR048432A1 (es) 2006-04-26
CN1946379A (zh) 2007-04-11
PL1732517T3 (pl) 2017-09-29
AU2005227095B2 (en) 2010-10-28
CA2562142A1 (en) 2005-10-06
RU2449778C1 (ru) 2012-05-10
CN1946379B (zh) 2012-05-16
KR20060130756A (ko) 2006-12-19
JP2007530510A (ja) 2007-11-01
JP4871258B2 (ja) 2012-02-08
TWI351957B (en) 2011-11-11
MXPA06010833A (es) 2006-12-15
PT1732517T (pt) 2017-08-03
TW200531693A (en) 2005-10-01
CA2562142C (en) 2012-06-05

Similar Documents

Publication Publication Date Title
ES2606342T3 (es) Composiciones para el cuidado bucal de sal estannosa y tripoli-fosfato de sodio y métodos
AR054114A1 (es) Composiciones farmaceuticas que comprenden imatinib y un retardador de la liberacion
EA200700566A1 (ru) Фармацевтические композиции, включающие леветирацетам, и способы их получения
PE20040418A1 (es) Nuevas formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
BRPI0514474A (pt) multiparticulados
PT1401501E (pt) Composicoes farmaceuticas orais com libertacao modificada do ingrediente activo
AR086971A2 (es) Composiciones orales y sistemas de liberacion
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
RS51271B (sr) Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid
AR054936A1 (es) Goma de mascar con pegajosidad reducida
ECSP055534A (es) Artículo absorbente que contiene una composición para el cuidado de la piel
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
AR054937A1 (es) Goma de mascar biodegradable
CL2007001270A1 (es) Metodo de control de enfermedades de plantas mendiante el uso de una composicion que comprende clorotalonilo en particulas solidas de entre 0,1 a 0,3 micrones.
HN2002000341A (es) Composiciones farmaceuticas para el tratamiento de la diabetis mellitus
CO5710195A1 (es) Forma cristalina alfa del ranelato de estronico,procedimien- to para su preparacion y composiciones farmaceuticas que la contienen
PE20030872A1 (es) Composicion farmaceutica del agonista parcial de 5ht4 tegaserod
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
AR026968A1 (es) Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
PE20060015A1 (es) Composiciones de liberacion prolongada que comprenden torasemida y un polimero formador de matriz
FR2894143B1 (fr) Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
BRPI0401103A (pt) Composição compósita, método para formar a mesma, composição modificada, e, método para formar a mesma
NO20013060L (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff

Legal Events

Date Code Title Description
FG Grant, registration